Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer

NCT02087241 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02087241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02087241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2014
Completion date
June 30, 2015
Enrollment
22 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

previously untreated stage iv non-squamous non small cell lung cancer